The long-term smell and taste-associated outcomes of coronavirus disease 2019 (COVID-19) using validated psychophysical tests.
AbbVie agrees to acquire Cerevel Therapeutics for $8.7bn
Share this article AbbVie will gain access to Cerevel’s neuroscience pipeline of multiple clinical-stage and preclinical candidates. Credit: © AbbVie Inc. All rights reserved. AbbVie